Skip to main content

SPRYCEL 140MG | MILLIONHEALTHPHARMA


SPRYCEL 140MG


DESCRIPTION

Sprycel,Sprycel 140mg,Sprycel 140mg tablet
Sprycel 140mg



Sprycel 140mg is a second-generation receptor Tyrosine kinase inhibitor. Which binds to Abl with less stringent conformational needed so it exhibits increased effectiveness compared to Imatinib even though with less selectivity. Unlike most RTK inhibitors,
Sprycel 140mg linked the active conformation of Bcr-Abl. Is required to treat patients with some Imatinib resistant forms of CML
Sprycel 140mg tablet which used as prescription drug under the guidance of doctor.

INDICATION

Sprycel,Sprycel 140mg,Sprycel 140mg tablet
Sprycel 140mg


Sprycel 140mg is used for the treatment for Chronic Myeloid Leukaemia: Recently diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.
Severe, increased, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
Sprycel 140mg tablet is used for the treatment for Acute Lymphoblastic Leukaemia: Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy

MECHANISM OF ACTION


Sprycel,Sprycel 140mg,Sprycel 140mg tablet
Sprycel 140mg


Sprycel 140mg is used for the treatment for Chronic Myeloid Leukaemia: Recently diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.
Severe, increased, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
Sprycel 140mg is used for the treatment for Acute Lymphoblastic Leukaemia: Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy

                                     

Sprycel,Sprycel 140mg,Sprycel 140mg tablet
Sprycel 140mg

                                                                                         PROPERTIES

                          Brand :Sprycel 
                          Ingredients : Dasatinib 
                          Strength : 140mg 
                          Manufactured : BMS India Pvt ltd 
                              Package : 60 tablets

PHARMACOKINETICS


Plasma protein binding is 96%
volume of distribution 2505 L
Extensively metabolized in humans, mainly by the cytochrome P450 enzyme 3A4.
Dasatinib excreted through the feces.
Half-life is 3-5 hours

DOSAGE MANAGEMENT


Sprycel,Sprycel 140mg,Sprycel 140mg tablet
Sprycel 140mg


• Newly diagnosed: The prescribed dose for Chronic Myeloid Leukaemia is starting 100 mg PO qDay (morning or evening). The drug will be raised to 140 mg qDay if insufficient response.
• The prescribed dose for Advanced CML is starting 140 mg PO qDay. The drug will increase to 180 mg qDay if insufficient reactions
• The prescribed dose for Acute Lymphoblastic Leukaemia is starting 140 mg PO qDay. The drug will increase to 180 mg PO qDay if insufficient reactions

PRECAUTION

Sprycel,Sprycel 140mg,Sprycel 140mg tablet
Sprycel 140mg


• When combination with chemotherapy the paediatric patients with Ph+ ALL treated, execute CBCs prior to initial of each block of chemotherapy and as clinically indicated; during consolidation blocks of chemotherapy, do CBCs every 2 days until recovery
• During treatment with Sprycel will causes Myelosuppression includes serious thrombocytopenia, neutropenia and Anemia may develop; may manage by dose interruption, dose reduction, or stopping of treatment; hematopoietic growth factor has been used with resistant myelosuppression.
• Sprycel 140mg will occur Hypokalaemia, hypomagnesemia, congenital QT interval prolongation, hepatic impairment
• Use with caution the drug Sprycel 140mg in patients who have or may develop prolongation of QT interval

SIDE EFFECTS

• Dyspnea
• Anorexia
• Arthralgia
• Asthenia
• Constipation
• Dizziness
• Musculoskeletal pain
• Febrile neutropenia
• Thrombocytopenia
• Mucosal inflammation
• Anemia
• Skin rash
• Infection
• Nausea
• Diarrhea
• Headache
• Haemorrhage
• Fatigue
• Pyrexia

PREGNANCY

Pregnancy category D: Sprycel 140mg tablet will resulted in fetal harm during pregnancy. Discuss with pregnant woman of the possible risk to a foetus.

LACTATION

Avoid breast feeding during Sprycel treatment .

STORAGE

Stored at 20°C – 25°C


CONTACT US

         PHONE NO   :+91-9940472902
         EMAIL           :millionhealthpharmaceuticals@gmail.com
         WEBSITE      :https://millionpharma.com/sprycel-140mg.php







Labels:

Comments

Post a Comment

Popular posts from this blog

Revolade 75mg tablets | Eltrombopag | MHP

                     Revolade 75mg tablet | Eltrombopag | MHP DESCRIPTION Revolade 75mg Eltrombopag is sold under the brand name Revolade and it is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body. Revolade 75mg  can reduces the risk of bleeding by increasing platelets in your blood. Revolade 75mg   which is used asprescription drug under the guidance of the medical practioners   INDICATION Revolade 75mg Revolade 75mg   tablet  isan anticancer medication which is; Indicated for the treatment of patients having Severe aplastic Anemia • First line treatment of severe aplastic Anemia • Treatment of refractory severe aplastic Anemia Indicated for the treatment to stimulate the growth and development of platelets in the bone marrow Primarily indicated for the treatment...
Post a Comment
Read more

Lenvatinib 4mg capsules | Lenvatinib | Millionpharma

Lenvatinib 4mg capsules | Lenvatinib | Millionpharma   DESCRIPTION  Lenvatinib 4mg Lenvatinib 4mg is a multi-kinase inhibitor and antineoplastic agents. It is a type of targeted treatment which target the specific cancer cells and hence reduces side effects caused by affected cells. Lenvatinib 4mg inhibits the protein which promotes cell division by preventing the cancer cell development. PRESCRIBED FOR  In adult, Lenvatinib 4mg tablet  is indicated for the treatment of metastatic, progressive, radioactive Differentiated Thyroid cancer. Lenvatinib 4mg in combination with everolimus is indicated in patients for the treatment of advance Renal Cell Carcinoma following treatment before anti-angiogenic therapy. Lenvatinib 4mg is also indicated for the first line treatment in patients suffering with unresectable hepatocellular carcinoma. MECHANISM OF ACTION  Lenvatinib is a tyrosine kinase inhibitor which has shown mainly ...
Post a Comment
Read more

TAGRISSO 40MG [ OSIMERITINIB 40MG ] | MILLIONHEALTHPHARMA

TAGRISSO 40MG [OSIMERITINIB 40MG] DESCRIPTION Tagrisso 40mg A Tagrisso 40mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib. Tagrisso 40mg is considered as third generation medicine, which is available in tablet form. Tagrisso 40mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity. The pharmacological category of Tagrisso 40mg is tyrosine kinase prohibitor. INDICATION Tagrisso 40mg A Tagrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients. Tagrisso 40mg is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment. MECHANISM OF ACTION Tagrisso 40mg Osimeritinib is similar in action when compared to other tyrosine kinase inhibitor drugs. Osi...
Post a Comment
Read more